ArticleBiomaterials2014
Dose ranging, expanded acute toxicity and safety pharmacology studies for intravenously administered functionalized graphene nanoparticle formulations.
Article in Biomaterials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.
- Evaluation of the effect of time on the distribution of zinc oxide nanoparticles in tissues of rats and mice: a systematic review.IET nanobiotechnology · 2016Pooled it
- First-in-human controlled inhalation of thin graphene oxide nanosheets to study acute cardiorespiratory responses.Nature nanotechnology · 2024Trial
- In situ sol-gel-sol transformation formed by sodium alginate realizes folic acid-modified chitosan nanoparticles to deliver hops β-acids for colorectal cancer therapy.Journal of nanobiotechnology · 2026Article
- Hemostatic B-knob-triggered microgels (BK-TriGs) to address bleeding in neonates.Science advances · 2026Article
- Thermo-responsive shape memory biomaterials with structural and physical adaptivity for scarless personalized nerve repair.Materials today. Bio · 2025Article
- Neuroprotective Effects of Low-Dose Graphenic Materials on SN4741 Embryonic Stem Cells Against ER Stress and MPTP-Induced Oxidative Stress.International journal of molecular sciences · 2025Article
- Graphene-based materials: an innovative approach for neural regeneration and spinal cord injury repair.RSC advances · 2025Review
- Angiotensin II-Induced Hypertrophy in H9c2 Cells Reveals Severe Cytotoxicity of Graphene Oxide.ACS omega · 2025Article
- Hepatotoxicity of Nanoparticle-Based Anti-Cancer Drugs: Insights into Toxicity and Mitigation Strategies.International journal of nanomedicine · 2025Review
- High Carbonyl Graphene Oxide Suppresses Colorectal Cancer Cell Proliferation and Migration by Inducing Ferroptosis via the System Xc-/GSH/GPX4 Axis.Pharmaceutics · 2024Article
- Two-dimensional nanomaterials: A multifunctional approach for robust for diabetic wound repair.Materials today. Bio · 2024Review
- Nanolevel Immunomodulators in Sepsis: Novel Roles, Current Perspectives, and Future Directions.International journal of nanomedicine · 2024Review
- Nanoparticle-based Gene Therapy for Neurodegenerative Disorders.Mini reviews in medicinal chemistry · 2024Review
- Adverse Effects of Non-Metallic Nanoparticles in the Central Nervous System.Materials (Basel, Switzerland) · 2023Review
- Gene Therapy for Regenerative Medicine.Pharmaceutics · 2023Review
- Synthesis and Functionalization of Graphene Materials for Biomedical Applications: Recent Advances, Challenges, and Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Graphene-Based Nanocomposites as Antibacterial, Antiviral and Antifungal Agents.Advanced healthcare materials · 2023Review
- The mechanical, optical, and thermal properties of graphene influencing its pre-clinical use in treating neurological diseases.Frontiers in neuroscience · 2023Review
- Understanding the Role of the Lateral Dimensional Property of Graphene Oxide on Its Interactions with Renal Cells.Molecules (Basel, Switzerland) · 2022Article
- Titanium Surfaces Modified with Graphene Oxide/Gelatin Composite Coatings for Enhanced Antibacterial Properties and Biological Activities.ACS omega · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Graphene nanoparticle dispersions show immense potential as multifunctional agents for in vivo biomedical applications. Herein, we follow regulatory guidelines for pharmaceuticals that recommend safety pharmacology assessment at least 10-100 times higher than the projected therapeutic dose, and present comprehensive single dose response, expanded acute toxicology, toxicokinetics, and respiratory/cardiovascular safety pharmacology results for intravenously administered dextran-coated graphene oxide nanoplatelet (GNP-Dex) formulations to rats at doses between 1 and 500 mg/kg. Our results indicate that the maximum tolerable dose (MTD) of GNP-Dex is between 50 mg/kg ≤ MTD < 125 mg/kg, blood half-life < 30 min, and majority of nanoparticles excreted within 24 h through feces. Histopathology changes were noted at ≥250 mg/kg in the heart, liver, lung, spleen, and kidney; we found no changes in the brain and no GNP-Dex related effects in the cardiovascular parameters or hematological factors (blood, lipid, and metabolic panels) at doses < 125 mg/kg. The results open avenues for pivotal preclinical single and repeat dose safety studies following good laboratory practices (GLP) as required by regulatory agencies for investigational new drug (IND) application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.